These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 1749695

  • 1. Stability of isoniazid, rifampin and pyrazinamide in suspensions used for the treatment of tuberculosis in children.
    Seifart HI, Parkin DP, Donald PR.
    Pediatr Infect Dis J; 1991 Nov; 10(11):827-31. PubMed ID: 1749695
    [Abstract] [Full Text] [Related]

  • 2. Improved Stability of Tuberculosis Drug Fixed-Dose Combination Using Isoniazid-Caffeic Acid and Vanillic Acid Cocrystal.
    Battini S, Mannava MKC, Nangia A.
    J Pharm Sci; 2018 Jun; 107(6):1667-1679. PubMed ID: 29462633
    [Abstract] [Full Text] [Related]

  • 3. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.
    Almeida D, Nuermberger E, Tasneen R, Rosenthal I, Tyagi S, Williams K, Peloquin C, Grosset J.
    Antimicrob Agents Chemother; 2009 Oct; 53(10):4178-84. PubMed ID: 19620331
    [Abstract] [Full Text] [Related]

  • 4. Isoniazid and its toxic metabolite hydrazine induce in vitro pyrazinamide toxicity.
    Tostmann A, Boeree MJ, Peters WH, Roelofs HM, Aarnoutse RE, van der Ven AJ, Dekhuijzen PN.
    Int J Antimicrob Agents; 2008 Jun; 31(6):577-80. PubMed ID: 18358703
    [Abstract] [Full Text] [Related]

  • 5. Radiosynthesis and bioimaging of the tuberculosis chemotherapeutics isoniazid, rifampicin and pyrazinamide in baboons.
    Liu L, Xu Y, Shea C, Fowler JS, Hooker JM, Tonge PJ.
    J Med Chem; 2010 Apr 08; 53(7):2882-91. PubMed ID: 20205479
    [Abstract] [Full Text] [Related]

  • 6. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.
    Malone RS, Fish DN, Spiegel DM, Childs JM, Peloquin CA.
    Am J Respir Crit Care Med; 1999 May 08; 159(5 Pt 1):1580-4. PubMed ID: 10228130
    [Abstract] [Full Text] [Related]

  • 7. Antagonism between isoniazid and the combination pyrazinamide-rifampin against tuberculosis infection in mice.
    Grosset J, Truffot-Pernot C, Lacroix C, Ji B.
    Antimicrob Agents Chemother; 1992 Mar 08; 36(3):548-51. PubMed ID: 1622164
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics of First-Line Drugs Among Children With Tuberculosis in Rural Tanzania.
    Justine M, Yeconia A, Nicodemu I, Augustino D, Gratz J, Mduma E, Heysell SK, Kivuyo S, Mfinanga S, Peloquin CA, Zagurski T, Kibiki GS, Mmbaga B, Houpt ER, Thomas TA.
    J Pediatric Infect Dis Soc; 2020 Feb 28; 9(1):14-20. PubMed ID: 30395239
    [Abstract] [Full Text] [Related]

  • 9. Anti-tuberculosis drug concentrations in tuberculosis patients with and without diabetes mellitus.
    Kumar AK, Chandrasekaran V, Kannan T, Murali AL, Lavanya J, Sudha V, Swaminathan S, Ramachandran G.
    Eur J Clin Pharmacol; 2017 Jan 28; 73(1):65-70. PubMed ID: 27651240
    [Abstract] [Full Text] [Related]

  • 10. Determination of rifampicin, isoniazid and pyrazinamide by high performance liquid chromatography after their simultaneous extraction from plasma.
    Smith PJ, van Dyk J, Fredericks A.
    Int J Tuberc Lung Dis; 1999 Nov 28; 3(11 Suppl 3):S325-8; discussion S351-2. PubMed ID: 10593712
    [Abstract] [Full Text] [Related]

  • 11. Age, nutritional status and INH acetylator status affect pharmacokinetics of anti-tuberculosis drugs in children.
    Ramachandran G, Hemanth Kumar AK, Bhavani PK, Poorana Gangadevi N, Sekar L, Vijayasekaran D, Banu Rekha VV, Ramesh Kumar S, Ravichandran N, Mathevan G, Swaminathan S.
    Int J Tuberc Lung Dis; 2013 Jun 28; 17(6):800-6. PubMed ID: 23676165
    [Abstract] [Full Text] [Related]

  • 12. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.
    Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N.
    Antimicrob Agents Chemother; 2007 Mar 28; 51(3):1011-5. PubMed ID: 17178794
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of isoniazid, rifampicin, pyrazinamide and ethambutol in HIV-infected Indian children.
    Mukherjee A, Velpandian T, Singla M, Kanhiya K, Kabra SK, Lodha R.
    Int J Tuberc Lung Dis; 2016 May 28; 20(5):666-72. PubMed ID: 27084822
    [Abstract] [Full Text] [Related]

  • 14. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
    Saito W, Nagayama N, Miyamoto M, Hara H, Suzuki J, Masuda K, Baba M, Tamura A, Nagai H, Akagawa S, Kawabe Y, Machida K, Kurashima A, Yotsumoto H.
    Kekkaku; 2003 Oct 28; 78(10):611-7. PubMed ID: 14621568
    [Abstract] [Full Text] [Related]

  • 15. Stability of bethanechol chloride, pyrazinamide, quinidine sulfate, rifampin, and tetracycline hydrochloride in extemporaneously compounded oral liquids.
    Allen LV, Erickson MA.
    Am J Health Syst Pharm; 1998 Sep 01; 55(17):1804-9. PubMed ID: 9775343
    [Abstract] [Full Text] [Related]

  • 16. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
    Dekker TG, Lötter AP.
    Int J Tuberc Lung Dis; 2003 Mar 01; 7(3):205-6. PubMed ID: 12661831
    [No Abstract] [Full Text] [Related]

  • 17. Short course preventive therapy for tuberculosis is successful in HIV-infected patients.
    Chaisson RE.
    Hopkins HIV Rep; 1998 May 01; 10(3):2-3. PubMed ID: 11365493
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Low Serum Concentrations of Rifampicin and Pyrazinamide Associated with Poor Treatment Outcomes in Children with Tuberculosis Related to HIV Status.
    Ramachandran G, Kumar AK, Kannan T, Bhavani PK, Kumar SR, Gangadevi NP, Banurekha VV, Sudha V, Venkatesh S, Ravichandran N, Kalpana S, Mathevan G, Sanjeeva GN, Agarwal D, Swaminathan S.
    Pediatr Infect Dis J; 2016 May 01; 35(5):530-4. PubMed ID: 26825153
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.